Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 18/20 | 0.83 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | FGR | P09769 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | SIK1 | P57059 | 2/20 | 0.46 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.46 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773926 | 0.94 | LCK (0.71) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL772892 | 0.91 | LCK (1.00) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL6487100 | 0.81 | LCK (0.72) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL773754 | 0.79 | LCK (0.74) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL22038674 | 0.79 | LCK (0.69) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL773380 | 0.78 | LCK (0.78) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL772868 | 0.77 | LCK (1.00) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL774820 | 0.77 | LCK (0.71) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL21875018 | 0.76 | LCK (0.67) | LCKABL1MAPK13EGFRERBB2 | |
| SCHEMBL774309 | 0.75 | LCK (1.00) | LCKABL1MAPK13EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | claimed |
| US-9084828-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2010120388-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | LCK 15/4885ABL1 30/4885MAPK13 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.